VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

Historical Holders from Q1 2014 to Q4 2025

Type / Class: Equity / Common Stock
Symbol: VRTX on Nasdaq
Shares outstanding: 256,606,920
Price per share: $453.36
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 231,722,881
Total reported value: $90,671,285,026
% of total 13F portfolios: 0.04%
Share change: -8,652,886
Value change: -$3,669,624,986
Number of holders: 1,492
Price from insider filings: $453.36

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) based on Schedule 13D/G filings

Filer	Ownership	Holdings Value	Nb Shares	Reporting Name	Report Period
Capital World Investors	11%	$13,916,470,694	28,739,975	Capital World Investors	31 Dec 2024
Capital Research Global Investors	5.7%	$7,038,788,492	14,536,344	Capital Research Global Investors	31 Mar 2025
FMR LLC	3.6%	$4,464,908,743	9,220,827	FMR LLC	31 Dec 2024

As of 30 Sep 2025, VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 1,492 institutional shareholders filing 13F forms. They hold 231,722,881 shares. of 256,606,920 outstanding shares (90%) .

Top 25 institutional shareholders own 65% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
Capital World Investors	10%	25,910,587	-9.8%	1.4%	$10,147,738,320
VANGUARD GROUP INC	9.4%	24,216,865	+1%	0.14%	$9,484,293,009
BlackRock, Inc.	8.7%	22,253,047	+1.7%	0.15%	$8,715,183,579
Capital Research Global Investors	6.5%	16,553,281	+2.8%	1.2%	$6,482,977,895
STATE STREET CORP	4.5%	11,606,000	-1.4%	0.16%	$4,545,373,840
JPMORGAN CHASE & CO	2.5%	6,434,778	+9.6%	0.16%	$2,520,139,212
GEODE CAPITAL MANAGEMENT, LLC	2.3%	5,973,745	+0.76%	0.15%	$2,328,861,818
WELLINGTON MANAGEMENT GROUP LLP	1.9%	4,772,042	-0.86%	0.33%	$1,868,922,529
Capital International Investors	1.8%	4,689,059	+78%	0.3%	$1,836,550,135
ALLIANCEBERNSTEIN L.P.	1.8%	4,522,586	+3.3%	0.56%	$1,771,225,581
LOOMIS SAYLES & CO L P	1.6%	4,122,128	+8.1%	1.9%	$1,614,390,030
JENNISON ASSOCIATES LLC	1.3%	3,454,947	-44%	0.79%	$1,353,095,435
FMR LLC	1.3%	3,303,768	-48%	0.07%	$1,293,887,557
MORGAN STANLEY	1.2%	3,108,405	-6.7%	0.07%	$1,217,377,330
PRICE T ROWE ASSOCIATES INC /MD/	1.2%	3,043,805	-3.7%	0.13%	$1,192,076,000
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC	1.1%	2,887,117	-5.9%	0.25%	$1,130,710,501
BANK OF AMERICA CORP /DE/	1.1%	2,840,424	+1.2%	0.08%	$1,112,423,583
Clearbridge Investments, LLC	1%	2,645,764	+73%	0.78%	$1,036,186,872
NORTHERN TRUST CORP	1%	2,627,887	-1.2%	0.13%	$1,029,185,665
AMERIPRISE FINANCIAL INC	0.89%	2,276,927	+4.4%	0.21%	$891,743,515
VICTORY CAPITAL MANAGEMENT INC	0.88%	2,247,566	+4.3%	0.5%	$787,317,055
JANUS HENDERSON GROUP PLC	0.83%	2,119,107	-19%	0.38%	$829,903,522
Invesco Ltd.	0.82%	2,096,797	+5.7%	0.13%	$821,189,454
Legal & General Group Plc	0.76%	1,952,297	+3.3%	0.17%	$764,597,601
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.71%	1,829,931	+3.2%	0.11%	$716,674,177

Institutional Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	1,684,548	$764,925,530	+$31,040,476			$453.36	60
2025 Q3	231,722,881	$90,671,285,026	-$3,669,624,986	$461,239,591	$711,553,846	$391.64	1,492
2025 Q2	240,735,835	$107,165,642,790	+$1,856,744,878	$493,290,312	$858,164,453	$445.20	1,543
2025 Q1	236,460,832	$114,649,907,000	+$567,851,688	$507,928,096	$659,725,474	$484.82	1,590
2024 Q4	235,736,164	$94,967,608,960	+$1,451,921,650	$577,997,207	$644,616,402	$402.70	1,527
2024 Q3	230,663,592	$107,260,536,111	-$1,912,629,012	$631,706,723	$731,988,295	$465.08	1,530
2024 Q2	234,228,682	$109,785,725,878	+$1,793,306,304	$738,983,992	$562,937,363	$468.72	1,532
2024 Q1	230,365,283	$96,187,796,058	-$1,702,488,567	$620,946,574	$559,847,135	$418.01	1,473
2023 Q4	2,137,308	$869,302,975	+$30,381,458			$406.89	20
2023 Q3	231,461,774	$80,538,639,566	-$565,917,173	$512,710,601	$532,146,469	$347.74	1,252
2023 Q2	231,381,541	$81,288,209,621	-$1,531,723,994	$320,698,800	$371,930,300	$351.91	1,253
2023 Q1	236,494,195	$74,500,103,740	+$552,261,083	$281,514,140	$349,705,514	$315.07	1,175
2022 Q4	235,262,091	$67,942,239,611	-$18,501,309	$284,060,662	$313,414,130	$288.78	1,189
2022 Q3	235,422,568	$68,198,221,131	+$549,977,421	$295,448,908	$353,421,074	$289.54	1,091
2022 Q2	228,243,856	$64,262,208,793	+$527,162,740	$317,335,358	$333,498,308	$281.79	1,078
2022 Q1	216,226,000	$56,349,811,280	+$112,062,951	$805,013,000	$520,128,968	$260.97	1,029
2021 Q4	223,667,909	$49,095,869,576	-$338,584,588	$453,278,000	$482,065,360	$219.60	1,001
2021 Q3	227,820,422	$41,299,928,890	-$34,446,984	$457,800,150	$419,576,287	$181.39	907
2021 Q2	225,510,678	$45,407,591,327	+$455,796,450	$602,676,015	$670,891,479	$201.63	951
2021 Q1	235,001,629	$50,462,178,162	-$678,647,446	$559,399,815	$508,452,070	$214.89	970
2020 Q4	237,714,161	$56,103,673,026	-$995,497,609	$318,845,000	$234,599,700	$236.34	938
2020 Q3	241,947,843	$65,793,581,523	-$118,311,363	$269,646,000	$249,520,000	$272.12	918
2020 Q2	242,342,339	$70,316,822,516	-$403,966,642	$312,032,160	$295,089,616	$290.31	942
2020 Q1	242,885,517	$57,767,796,924	+$325,722,381	$232,992,012	$263,288,017	$237.95	832
2019 Q4	243,373,734	$53,285,941,276	-$520,182,793	$327,534,000	$328,430,000	$218.95	794
2019 Q3	245,610,278	$41,608,365,876	+$12,610,996	$266,071,000	$215,825,000	$169.42	690
2019 Q2	241,199,190	$44,221,976,254	+$1,519,940,542	$239,164,000	$283,295,000	$183.38	697
2019 Q1	244,492,921	$44,967,052,322	+$391,208,371	$186,285,000	$220,091,000	$183.95	718
2018 Q4	243,049,035	$40,268,390,809	+$323,356,770	$341,044,000	$357,555,000	$165.71	685
2018 Q3	233,927,268	$45,077,454,854	+$4,072,080	$299,711,000	$327,561,000	$192.74	681
2018 Q2	241,037,840	$40,950,479,156	+$446,056,404	$255,411,000	$256,363,000	$169.96	679
2018 Q1	239,932,166	$39,097,184,363	+$125,435,263	$180,343,416	$190,004,198	$162.98	668
2017 Q4	239,011,569	$35,811,772,434	+$292,550,321	$151,967,726	$178,475,000	$149.86	629
2017 Q3	237,693,252	$36,107,897,628	+$312,514,025	$216,702,000	$291,136,000	$152.04	601
2017 Q2	235,990,193	$30,397,304,403	+$9,586,449	$116,685,000	$328,482,000	$128.87	563
2017 Q1	235,546,990	$25,756,054,334	+$2,164,927,252	$202,973,000	$210,176,000	$109.35	505
2016 Q4	236,227,545	$17,407,196,042	-$343,484,357	$86,406,000	$101,007,000	$73.67	465
2016 Q3	240,642,156	$20,977,541,687	+$81,599,033	$61,351,000	$68,511,000	$87.21	474
2016 Q2	239,945,525	$20,642,106,416	+$255,630,152	$51,369,000	$65,871,000	$86.02	467
2016 Q1	234,004,074	$18,599,807,173	+$171,000,794	$60,666,000	$48,081,000	$79.49	481
2015 Q4	234,487,739	$29,503,926,526	-$14,621,109	$103,458,000	$68,070,000	$125.83	506
2015 Q3	231,282,099	$24,085,221,645	+$687,286,946	$88,022,000	$61,514,000	$104.14	480
2015 Q2	226,994,444	$28,033,026,068	-$367,752,515	$102,525,000	$71,686,000	$123.48	491
2015 Q1	233,290,652	$27,527,924,072	+$466,178,242	$82,676,000	$64,509,000	$117.97	468
2014 Q4	229,634,542	$27,283,524,520	-$519,280,371	$402,986,000	$257,096,000	$118.80	465
2014 Q3	233,192,423	$26,189,310,928	+$763,833,066	$376,672,000	$262,550,000	$112.31	421
2014 Q2	226,872,140	$21,479,095,738	+$285,246,274	$591,876,000	$590,144,000	$94.68	403
2014 Q1	223,372,507	$15,790,656,300	+$98,578,564	$296,290,000	$191,508,000	$70.72	387